Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Cited by 26 Publications

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )
PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	M3Tnb2Z2dmO2aX;uJGF{e2G7	MUGwMlXDqM7:TR?=	NUnvfYdKOjRiaB?=	NFLlTmF4[XSnch?=	NHPoelFud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>?	MX6yOVEzOzB6Mh?=
Eca109	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jIVFAvPS9{LkWvOUDPxE1?	M4i0e\|I1NzR6L{eyJIg>	MlLte4F1\XJ?	NVWwVVV3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	M4XJWlI2OTJ\|MEiy
Eca109	M1zrdmZ2dmO2aX;uJGF{e2G7	MWGwMlXDqM7:TR?=	MkfWOk8yOi9{NDDo	NF3kbYh4[XSnch?=	MUXpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi	Mm\SNlUyOjNyOEK=
Eca109	MoPUSpVv[3Srb36gRZN{[Xl?	MViwMlXDqM7:TR?=	MmfiNlQhcA>?	MX73ZZRmeg>?	MXPpcohq[mm2czDj[YxtKGmwdnHzbY9v	M2j6dFI2OTJ\|MEiy
Eca109	NYjndm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXT3flgyOC53wrFOwG0>	Mln0NlQhcA>?	NYrvPYZHf2G2ZYK=	M3foWIlv\HWlZYOgS\|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU>	MlXzNlUyOjNyOEK=
Eca109	M3TWfWZ2dmO2aX;uJGF{e2G7	MkTqNE42NzFizszN	MlzhNlQhcA>?	MXP3ZZRmeg>?	NWjiUI9l\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu\|rqEMjDhcoQhVU2SMh?=	MlHZNlUyOjNyOEK=
SW1116	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;WNE42NzFxMj:1JO69VQ>?	NIDDRmY1QCCq	NXLLWmdDTE2VTx?=	NVO1fo92\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>?	M4XuclI1QDd2Mki2
LOVO	NVvydVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jXVlAvPS9zL{KvOUDPxE1?	MknBOFghcA>?	NWizc2xETE2VTx?=	NFPHUGRmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v	NXrFflhWOjR6N{SyPFY>
SW1116	MVPGeY5kfGmxbjDBd5NigQ>?	M1j2bFExKM7:TR?=	MVu0PEBp	NY\JVXZzTE2VTx?=	NVzu[Yl[cW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk	NH7z[HgzPDh5NEK4Oi=>
LOVO	Mlq5SpVv[3Srb36gRZN{[Xl?	MoK4NVAh\|ryP	MYm0PEBp	Mke1SG1UVw>?	MoT6bY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm\|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj	MojYNlQ5PzR{OE[=
SW1116	NFnnXYhCeG:ydH;zbZMhSXO\|YYm=	MVixNEDPxE1?	M2XCZ\|Q5KGh?	MUPEUXNQ	NGLESpBmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM>	M1XXc\|I1QDd2Mki2
LOVO	NEPsNXZCeG:ydH;zbZMhSXO\|YYm=	MXOxNEDPxE1?	NG[yXXQ1QCCq	NXTTSoJkTE2VTx?=	MX7lcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:\|aYO=	M{fnclI1QDd2Mki2
RPMI-8226	Mn3lRZBweHSxc3nzJGF{e2G7	MUSxM\|Ih\|ryP	M1L3WFQ5Nzd{L{m2JIg>	MlzqSG1UVw>?	M{nWNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MknJNlQ5OzNzMEi=
OPM-2	MVnBdI9xfG:\|aYOgRZN{[Xl?	NH\xdJQyNzJizszN	M1i0[FczNzl4L{GyNEBp	NV\mN5RLTE2VTx?=	NEDMUW1qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MnS0NlQ5OzNzMEi=
JJN3	MkXsRZBweHSxc3nzJGF{e2G7	NF7JW\|cxNjVxMTFOwG0>	M2XpdFI1NzR6IHi=	NHX4OI1FVVOR	M{LqTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MnjrNlQ5OzNzMEi=
NCI-H929	MoXzRZBweHSxc3nzJGF{e2G7	MYOxM\|Ih\|ryP	MYS3Nk86Pi9zMkCgbC=>	MWDEUXNQ	MW\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MmfvNlQ5OzNzMEi=
RPMI-8226	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[zUVh7OS9{IN88US=>	MljDNlQwPDhxN{KgbC=>	NF;tUnZFVVOR	MVLh[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	NYf0RoFIOjR6M{OxNFg>
OPM-2	NFfLdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f0c\|EwOiEQvF2=	NIr2cpUzPC92OD:3NkBp	M3LXWmROW09?	M{LsRoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	MX2yOFg{OzFyOB?=
JJN3	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;iNE42NzFizszN	MYiyOE81QC95MjDo	NGjQZ\|RFVVOR	NVjqb5VL[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	NXTjRYE{OjR6M{OxNFg>
NCI-H929	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHLXZgyNzJizszN	MVqyOE81QC95MjDo	MV7EUXNQ	M4jxcoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	NWjqToI5OjR6M{OxNFg>
HeLa	M2O1ZWtqdmG\|ZTDBd5NigQ>?				M{HtemtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE>	NEnW[5AzPDd6MEC5PC=>
HeLa	NV\lNXJrU2mwYYPlJGF{e2G7				NVHq[WtoU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz	MW[yOFc5ODB7OB?=
HeLa	Moi3T4lv[XOnIFHzd4F6				MkX2T4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=>	NIHkNGwzPDd6MEC5PC=>
HeLa	NFvnfmpMcW6jc3WgRZN{[Xl?				NXu0Z296U2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>?	Ml[4NlQ4QDByOUi=
NB4	NGnHTpVHfW6ldHnvckBCe3OjeR?=	NFfRVIMzNjVxNT:3MlUwOTBizszN	NGLtT5UzPCCq	MknzSG1UVw>?	NYrkRVc6cW6lcnXhd4ViKHSqZTDlfJBz\XO\|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>?	NVLSVolmOjR2OES4O\|A>
CD4+ CD25− T	Mn3hSpVv[3Srb36gRZN{[Xl?	NUftenJQOS93IN88US=>			M2C5UpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	NEnNS5MzPDR5NkO2NC=>
BV-173	MVfBdI9xfG:\|aYOgRZN{[Xl?	NUH4Npc6OC5{NT:wMlUwOC55NT:xJO69VQ>?	NH36bo41QC95Mj:5OkBp	NIjIcHDDqFCEUx?=	NYX1OmwzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	MY[yOFQzOzZzMx?=
ML-1	MX;BdI9xfG:\|aYOgRZN{[Xl?	MX6wMlI2NzBwNT:wMlc2NzFizszN	NGL0XlM1QC95Mj:5OkBp	NVO4UJh6yqCSQmO=	MUDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	MoLwNlQ1OjN4MUO=
HL-60	NX3VPWg3SXCxcITvd4l{KEG\|c3H5	NE\FdIsxNjJ3L{CuOU8xNjd3L{Gg{txO	MoDCOFgwPzJxOU[gbC=>	NV;scG9qyqCSQmO=	NVOzRXhycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	NU\WblVnOjR2MkO2NVM>
KG-1a	NULIR45RSXCxcITvd4l{KEG\|c3H5	NV2xTHhXOC5{NT:wMlUwOC55NT:xJO69VQ>?	M1XwNlQ5Nzd{L{m2JIg>	NG\Nd23DqFCEUx?=	MlPIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MX:yOFQzOzZzMx?=
BV-173	M4q5WGZ2dmO2aX;uJGF{e2G7	MVmyOVAwPTBybl2=	MX20PEBp	NVTacnlmyqCSQmO=	MkLJbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	NEnnUmozPDR{M{[xNy=>
CEM	MWjGeY5kfGmxbjDBd5NigQ>?	M3TV[VI2OC93MEDuUS=>	NX3Rc4w{PDhiaB?=	MXhCpHBDWw>?	M2HkfIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	MWiyOFQzOzZzMx?=
HL-60	MnjFSpVv[3Srb36gRZN{[Xl?	M1\EOVI2OC93MEDuUS=>	MXS0PEBp	MmTJxsBRSlN?	MVfpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	NHjB[IMzPDR{M{[xNy=>
ML-1	NV3l[HgxTnWwY4Tpc44hSXO\|YYm=	MWSyOVAwPTBybl2=	MmHQOFghcA>?	Mn;5xsBRSlN?	M1S0d4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	M3f6WVI1PDJ\|NkGz
DLD-1	MkfJSpVv[3Srb36gRZN{[Xl?	Mn;INlUxNzVyMH7N	M3X2fFQ5KGh?	NXXWbHhsyqCSQmO=	MWPkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm	NITJUmczPDR{M{[xNy=>
HCT-116	MVLGeY5kfGmxbjDBd5NigQ>?	MmK3NlUxNzVyMH7N	Moi5OFghcA>?	M2PVUuKhWEKV	MmrJ[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>?	MVmyOFQzOzZzMx?=
U937-A/E-9/14/18	MnLWRZBweHSxc3nzJGF{e2G7	MkHPNE4xOS9yLkGvNU8yOCEQvF2=	NITmcoI1QCCq		NXXoUIpEcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NF\CbFczPDNyMES1Oi=>
HT29	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGHNXpg4OiCq		MYjJR\|UxRTF2MEFCtVE4QSEQvF2=	MlvBNlQyPzJyNkG=
SW48	NHHaRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkO3O\|IhcA>?		MmiwTWM2OD1zNT6yxtE3NjJizszN	M4jQSlI1OTd{ME[x
HCT116	NWLTfJpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mmm1O\|IhcA>?		MoHJTWM2OD1zLkhCtVAvPCEQvF2=	M4SydVI1OTd{ME[x
HepG2	M3vEcWZ2dmO2aX;uJGF{e2G7	M{m5elAvPS9zIN88US=>	NV76SoZbOjRiaB?=	NWjSZYU3TE2VTx?=	MV71dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>?	NHrMRXkzPDF2Nki3OC=>
LS174T	NHXV[pBHfW6ldHnvckBCe3OjeR?=	NVfYe4NtOC53L{Gg{txO	NE\HeVAzPCCq	MXfEUXNQ	MkLycIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO=	MXKyOFE1Pjh5NB?=
HepG2	MorqRZBweHSxc3nzJGF{e2G7	MWmxM\|ExNzFyMDFOwG0>	MWe3JIQ>	MmLlSG1UVw>?	MljYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NF65OZUzPDF2Nki3OC=>
LS174T	Mon5RZBweHSxc3nzJGF{e2G7	NV\LWJY4OS9zMD:xNFAh\|ryP	MlPIO{Bl	NGHhcZpFVVOR	NWHTTodTcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M2DtdVI1OTR4OEe0
QBC-939	NHrOOoxCeG:ydH;zbZMhSXO\|YYm=	NYfGbHFUOS9zMD:xNFAh\|ryP	M1\KRlch\A>?	MomzSG1UVw>?	NVPXdHdscW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MXeyOFE1Pjh5NB?=
U251	NWn4[pZMSXCxcITvd4l{KEG\|c3H5	MWCxM\|ExNzFyMDFOwG0>	MmP6O{Bl	NVXrbWhOTE2VTx?=	MUjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MmfNNlQyPDZ6N{S=
HL-60	NHzEboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX2xJO69VQ>?	NIn6fow1QCCq		NWjpXYZOcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36=	NVrpWJM5OjRyMECzNlQ>
MDA‑MB‑453	NEjleIVHfW6ldHnvckBCe3OjeR?=	M{Kyd\|AvOi9zIN88US=>	MYW3NkBp		M4j0coNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	M1rPOVI{QDR2MkK4
HCC1569	NHjISZBHfW6ldHnvckBCe3OjeR?=	NECxRXIxNjJxMTFOwG0>	MUW3NkBp		M2LEXoNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	MoG3NlM5PDR{Mki=
BT‑474	Mn7LSpVv[3Srb36gRZN{[Xl?	M{TpfVAvOi9zIN88US=>	MlLUO\|IhcA>?		MnO2Z4F2e2W\|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg	NWjGVXhqOjN6NESyNlg>
AGS	MnHYRZBweHSxc3nzJGF{e2G7	MojtOU8yOC9{MD:1NEDPxE1?	MV20POKhcMLi	NU[3XXhZTE2VTx?=	MkfhbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA>	M3j6dlI{PTh{N{i0
A549	NWfQdZZwSXCxcITvd4l{KEG\|c3H5	Mk[xOU8yOC9{MD:1NEDPxE1?	NXv3RYU3PDkEoHlCpC=>	MkHkSG1UVw>?	NYHvOFhzcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB?	NXr0VphVOjN3OEK3PFQ>
AGS	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYG1M\|ExNzJyL{WwJO69VQ>?	NYTiUGJJPDkEoHlCpC=>	M2\DUmROW09?	MnLrbY5lfWOnczDHNk9OKHCqYYPlJIFzemW\|dNMg	MWKyN\|U5Ojd6NB?=
Kasumi-1	NYXOT25GSXCxcITvd4l{KEG\|c3H5	NFX4doYxNjVizszN	NXrqZmZKPDkEoHlCpC=>		MX7k[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2\|Yx?=	M3mz[FI{PDl\|M{S4
OCI-AML3	NVHETIIxSXCxcITvd4l{KEG\|c3H5	NFric2UzNjVizszN	MoL1OFjDqGkEoB?=		MnrO[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	NHLHd2ozOzR7M{O0PC=>
MV4-11	NH;6[ZVCeG:ydH;zbZMhSXO\|YYm=	MmPLNk42KM7:TR?=	M3juO\|Q5yqCqwrC=		MnOy[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	M{PYfFI{PDl\|M{S4
NK	M{W2OmN6fG:2b4jpeJkhSXO\|YYm=	NVnJbIZGOC5yMj2yNEDPxE1?	MlrPOUBl		NXzBWHN7\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26\|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?=	Mk\ENlM{OjhyOEi=
NK	NGfhUVdCeG:ydH;zbZMhSXO\|YYm=	NID2bWYxNjB{LUKwJO69VQ>?	M2DqR\|Uh\A>?		NXXpUWhn\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm	Mm\BNlM{OjhyOEi=
NK	NGD4UXVHfW6ldHnvckBCe3OjeR?=	Mom3NE4xOS1{MDFOwG0>	NVXGWXNKPSCm		MoGwZ4F2e2W\|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=>	M{jFOFI{OzJ6MEi4
MOLT4/DNR	Mm\mSpVv[3Srb36gRZN{[Xl?	NVvwTmdwPSEQvF2=	MnTzOEBl		MXPy[YR2[2W\|IFHCR2IyKG2UTlGg[ZhxemW\|c3nvci=>	NUTLdGl2OjNyNkC1O\|A>
Jurkat/DOX	NXi3SFdmTnWwY4Tpc44hSXO\|YYm=	MX21JO69VQ>?	NV22cmJyPCCm		NEXp[mlz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>?	MmnTNlMxPjB3N{C=
MOLT4/DNR	MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIn2bmk2KM7:TR?=	MXm0JIQ>		NXTtdZA4emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=>	M2D4NVI{ODZyNUew
Jurkat/DOX	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPUOUDPxE1?	MojMOEBl		NYX3R3VVemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=>	M3LHTVI{ODZyNUew
ccRCC	M2\HNmFxd3C2b4Ppd{BCe3OjeR?=	M1i5b\|AvODFvMUFOwG0>	M1nhelczKGh?	NHzXcJNFVVOR	MVPoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	MVWyNlgzPjR4Nx?=
TNBC	NH3aU49CeG:ydH;zbZMhSXO\|YYm=	NVPvTm1DOC5yMT2xNO69VQ>?	MlrWO\|IhcA>?	MXHEUXNQ	MljNbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>?	MVKyNlgzPjR4Nx?=
A498	NHf5RlFCeG:ydH;zbZMhSXO\|YYm=	MUGwMlAyNTFyzszN	NFOwO4Y4OiCq	NFHzXm9FVVOR	MnHUbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	M2fSVlIzQDJ4NE[3
KIJ265T	MoK1RZBweHSxc3nzJGF{e2G7	MnyzNE4xOS1zMN88US=>	Mk\zO\|IhcA>?	MUTEUXNQ	NUj0NZdkcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>?	NUjHWIZqOjJ6Mk[0Olc>
MDA-231	MXzBdI9xfG:\|aYOgRZN{[Xl?	NYT6bGVYOC5yMT2xNO69VQ>?	M3;HPFczKGh?	MXzEUXNQ	NGTxeWJqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	MWmyNlgzPjR4Nx?=
BT-20	Moj5RZBweHSxc3nzJGF{e2G7	NVj6dVl1OC5yMT2xNO69VQ>?	NID4dVk4OiCq	MVjEUXNQ	M2jVRYlv\HWlZYOgd5lv\XKpaYP0bYMhemW\|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4>	NWPFPHh{OjJ6Mk[0Olc>
U937	NV7C[XV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHjTZNLPS1{MDFOwG0>	MX:yOE81QC95MjDo		NITBRoNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NUnEW\|FNOjJ5NkewNlE>
HL60	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LXUVUuOjBizszN	MVOyOE81QC95MjDo		MonKbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	MlzRNlI4PjdyMkG=
U937	Mn;hRZBweHSxc3nzJGF{e2G7	MWGxOUDPxE1?	MXiyOE81QC95MjDo		MljhbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M{i3XVIzPzZ5MEKx
HL60	M3L2d2Fxd3C2b4Ppd{BCe3OjeR?=	MVOxOUDPxE1?	NGnMWIkzPC92OD:3NkBp		MV3pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M3uxN\|IzPzZ5MEKx
LS411N	NXzxcFZ4SXCxcITvd4l{KEG\|c3H5	NXTz[nZbOC53IN88US=>	MYC3NkBp		NWjpbFJjcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs	M{XSXVIzPDZzNkm1
MDA-MB-231	MlztRZBweHSxc3nzJGF{e2G7	MU[xNEDPxE1?	NULvfYhpPDhiaB?=		MnTFdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MlG2NlE5QDd4OUe=
MCF-7	M4jPPGFxd3C2b4Ppd{BCe3OjeR?=	NY[zZ3E5OTBizszN	NHXqR2s1QCCq		NXrM[YF1emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MlPMNlE5QDd4OUe=
A375	NUO4Z5Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPjdXFROC53IN88US=>	NYHD[\|JDOS93L{ig[C=>		NYfsOpRTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MnPpNlE4QTZ4MkK=
SKMEL1	NHi2bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUewMlUh\|ryP	MoHiNU82NzhiZB?=		NUjTSFhxcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MknFNlE4QTZ4MkK=
SKMEL3	M1LmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYOxbWNzOC53IN88US=>	NXrRUWp4OS93L{ig[C=>		M2Lab4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	NGXNdZYzOTd7Nk[yNi=>
SKMEL28	NFjTe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLmc2wxNjVizszN	MUSxM\|UwQCCm		M{jPR4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	MXSyNVc6PjZ{Mh?=
MeWo	NHq2VmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:3cVAvPSEQvF2=	Moe5NU82NzhiZB?=		MkTNbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	MoDnNlE4QTZ4MkK=
B16	NHv6cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYf3OWdwOC53IN88US=>	MWSxM\|UwQCCm		M1LYVolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	M{jBSVIyPzl4NkKy
Ly 1	NITrT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGr5N5MzPCCq		M3\ud2lEPTB;Nz6zJO69VQ>?	M1zsU\|IyPzd{MES5
Ly 7	NWO3dGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXiyOEBp		NWL3dZBqUUN3ME2xNE44KM7:TR?=	M124blIyPzd{MES5
Su-DHL6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn\RNlQhcA>?		M{S1[2lEPTExvK6yNEDPxE1?	MlXoNlE4PzJyNEm=
Ly 10	NHzvfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVf2e3VDOjRiaB?=		MU\JR\|Ux97zgMkCg{txO	MWWyNVc4OjB2OR?=
RIVA	M3\C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV:yOEBp		MkHSTWM2OO,:nkKwJO69VQ>?	MlfZNlE4PzJyNEm=
Su-DHL2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoPaNlQhcA>?		MXnJR\|Ux97zgMkCg{txO	M3:wTlIyPzd{MES5
Ly 1	NVnpRlRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDZOFghcA>?		M2jpXmlEPTB;MD6zOEDPxE1?	Mnj5NlE4PzJyNEm=
Ly 7	NX72S3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFLpelQ1QCCq		Ml7XTWM2OD1yLkCyOUDPxE1?	MnjaNlE4PzJyNEm=
Su-DHL6	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlriOFghcA>?		MmjBTWM2OO,:nkKwJO69VQ>?	MVyyNVc4OjB2OR?=
Ly 10	M2\teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXi0PEBp		NF;OdmFKSzVyPUGuPEDPxE1?	M2fpVVIyPzd{MES5
RIVA	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmPpOFghcA>?		NWrzV2s{UUN3MP-8olIxKM7:TR?=	NWflVHV6OjF5N{KwOFk>
Su-DHL2	M2njU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn;qOFghcA>?		MYrJR\|UxRTF5LkSg{txO	M3jWV\|IyPzd{MES5
Ly 1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXe3NkBp		NGHZN2xKSzVyPUCuNFEh\|ryP	NIHINHozOTd5MkC0PS=>
Ly 7	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn:0O\|IhcA>?		NWX1UYFCUUN3ME2wMlAyQCEQvF2=	NXTBV5ZwOjF5N{KwOFk>
Su-DHL6	NGPWdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHXLTGM4OiCq		MVvJR\|UxRTFwNjFOwG0>	MmLiNlE4PzJyNEm=
Ly 10	NXXC[2VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm\pO\|IhcA>?		NFLpcpZKSzVyPUGuNkDPxE1?	NITTUYIzOTd5MkC0PS=>
RIVA	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWK3NkBp		M3LlT2lEPTExvK6yNEDPxE1?	MXeyNVc4OjB2OR?=
Su-DHL2	M4fuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjQWlQ4OiCq		NYLRUJZZUUN3ME2xNU4zKM7:TR?=	NIr3VIwzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	+ Expand Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Formulation: Decitabine is dissolved in sterile PBS . Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Deoxycytidine

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03828084	Not yet recruiting	Healthy	EpiDestiny Inc.	April 3 2019	Phase 1
NCT03828084	Not yet recruiting	Healthy	EpiDestiny Inc.	April 3 2019	Phase 1
NCT03844815	Not yet recruiting	Acute Myeloid Leukemia	University of Chicago\|AbbVie	April 10 2019	Phase 1
NCT03844815	Not yet recruiting	Acute Myeloid Leukemia	University of Chicago\|AbbVie	April 10 2019	Phase 1
NCT03875287	Not yet recruiting	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals	March 2019	Phase 1
NCT03875287	Not yet recruiting	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals	March 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Cited by 26 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Cited by 26 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)